Breaking News: Vaccine to treat celiac disease is closer than ever

ImmusanT, a biotechnology company out of Massachusetts is working on developing Nexxax2, a vaccine which could potentially treat or prevent celiac disease.  As of this week, they finished the Phase 1 b trial.  This means that we are now closer than ever to finding some sort of “cure” or treatment for celiac beyond the dietary fix.

The idea of Nexvax2 is that a small dose would be given to patients with the celiac gene or diagnosis first, and the amount would gradually increase, building up resistance without harmful side effects.

Next comes the Phase 2 trial, which is a key step.  About 63 percent of drugs make it to this phase. Later in 2017 the study will begin recruiting participants for the trial.  However, the vaccine would not initially be intended to eliminate the gluten free diet, but rather would treat gluten exposure and hopefully eventually be used as a full vaccine without need for the diet.

A main motivation for the need for this type of vaccine is that many celiac patients continue to have intestinal damage and symptoms long after following the gluten free diet.

Sources: 1, 2

Chloe Dyer

About Chloe Dyer

Chloe graduated from UMaine Orono with a BA in Mass Communication and a minor in Political Science. In addition to writing for the BDN, she has been Editor in Chief of Her Campus UMaine, Contributing Editor of Odyssey UMaine, and a Staff Writer for The Maine Campus . She has known about her Celiac Disease for about two years and has been eating gluten free as well as sometimes dairy free. She is from Chebeague Island, Maine, where she grew up, but has also lived in Cleveland, Ohio, and Blagoevgrad, Bulgaria in addition to Orono.